预约演示
更新于：2025-03-28
Evocalcet
依伏卡塞
更新于：2025-03-28
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (2018-03-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H26N2O2 |
InChIKeyRZNUIYPHQFXBAN-XLIONFOSSA-N |
CAS号870964-67-3 |
关联
31
项与 依伏卡塞 相关的临床试验CTR20241174
依伏卡塞片的生物等效性试验
CTR20241321
依伏卡塞片人体生物等效性试验
CTR20240573
中国健康受试者空腹及餐后状态下单次口服依伏卡塞片（规格：2mg）的一项单中心、随机、开放、两制剂、两序列、两周期交叉生物等效性试验
100 项与 依伏卡塞 相关的临床结果
登录后查看更多信息
100 项与 依伏卡塞 相关的转化医学
登录后查看更多信息
100 项与 依伏卡塞 相关的专利（医药）
登录后查看更多信息
66
项与 依伏卡塞 相关的文献（医药）2025-01-01BMJ Case Reports
Severe hypophosphataemia following denosumab administration successfully managed using a calcimimetic agent
Article
作者: Omori, Makiko ; Ikeda, Yuhachi ; Sakai, Tomoyuki ; Matsukawa, Yukihiro
Denosumab, an anti-RANKL antibody, induces bone metabolism to a low-turnover bone status by arresting osteoclast activity. Frequent adverse events include infusion reactions, fever and hypocalcaemia but not hypophosphataemia. We report a case of severe hypophosphataemia associated with secondary hyperparathyroidism following denosumab administration in a young boy with recurrent osteosarcoma who was successfully treated with evocalcet. He developed hypocalcaemia and severe refractory hypophosphataemia after receiving denosumab for bone metastases despite calcium, cholecalciferol and phosphorus supplementation. Laboratory data revealed secondary hyperparathyroidism due to denosumab-induced hypocalcaemia as the cause of hypophosphataemia. Evocalcet contributed to the normalised parathyroid hormone and phosphorus levels, allowing the discontinuation of phosphorus supplementation. This case highlights the complexity of managing electrolyte imbalances induced by bone-modifying agents, such as denosumab, underscoring the importance of monitoring bone metabolism markers and the potential effectiveness of evocalcet in managing drug-induced secondary hyperparathyroidism and hypophosphataemia.
2025-01-01Case Reports in Endocrinology
Successful Treatment With Evocalcet Against Familial Hypocalciuric Hypercalcemia Type 3 (FHH3) Identified by AP2S1 Gene Mutation (p.Arg15Leu)
Article
作者: Hasegawa, Yutaka ; Yamabe, Daisuke ; Chida, Ai ; Nata, Koji ; Yan, Hirotaka ; Oda, Tomoyasu ; Chiba, Hiraku ; Segawa, Toshie ; Kinno, Hirofumi ; Ishigaki, Yasushi ; Takahashi, Yoshihiko ; Chiba, Yusuke
Background: Familial hypocalciuric hypercalcemia type 3 (FHH3) is a rare hereditary disorder caused by a heterozygous AP2S1 gene mutation, characterized by hypocalciuria and hypercalcemia due to impaired intracellular signal transduction of calcium (Ca)‐sensing receptors (CaSRs). All affected patients harbored a heterozygous missense mutation at the Arg15 residue of the encoded AP2σ1.Case Presentation: A 21‐year‐old female was referred to our hospital with hypercalcemia and reduced bone mineral density (BMD) detected during a preoperative examination for scoliosis surgery. She had a developmental disorder and exhibited hypocalciuria on urinalysis. Genetic testing revealed a heterozygous AP2S1 gene mutation (p.Arg15Leu), and the patient was diagnosed with FHH3. In the present case, we investigated the effects of evocalcet, a newly approved CaSR agonist. Treatment with evocalcet gradually decreased and normalized the serum Ca level, and promoted improvements in bone metabolism, without serious adverse events.Conclusion: Evocalcet may be a promising therapeutic candidate for symptomatic FHH3.
2024-11-01BMJ Case Reports
Paradoxical cerebral embolism caused by patent foramen ovale in a patient with multiple endocrine neoplasia type 1 and severe primary hyperparathyroidism
Article
作者: Shimano, Hitoshi ; Matsuda, Takaaki ; Sekiya, Motohiro ; Osaki, Yoshinori
A man in his late 30s with gait difficulty, dysarthria, impaired consciousness and polyuria was diagnosed with left thalamic infarction. Hypercalcaemia (3.52 mmol/L (2.15–2.52)), high intact-parathyroid hormone (i-PTH) levels (88.8 pmol/L (1.1–6.9)) and high D-dimer levels (14.7 mg/L (<1.0)) were identified, followed by a positive microbubble test on transesophageal echocardiogram, suggesting high-risk patent foramen ovale (PFO) for ischaemic stroke. Paradoxical cerebral embolism via PFO, complicated by a hypercoagulable state and hypercalcemic dehydration, was considered. Polyglandular parathyroid hyperplasia, plus radiolucent mandibular tumours, suggested multiple endocrine neoplasia type 1 (MEN1) or hyperparathyroidism-jaw tumour syndrome. Genetic testing confirmed MEN1. Treatment was 24 mg of oral evocalcet and total parathyroidectomy with forearm autotransplantation, resulting in improved serum calcium and i-PTH levels. Finally, he underwent transcatheter PFO closure. We emphasise careful, etiological pursuit in young-onset stroke and the usefulness of genetic testing in differentiating hyperparathyroidism associated with mandibular tumours.
100 项与 依伏卡塞 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高钙血症 | 日本 | 2019-12-20 | |
| 原发性甲状旁腺功能亢进症 | 日本 | 2019-12-20 | |
| 甲状旁腺肿瘤 | 日本 | 2019-12-20 | |
| 继发性甲状旁腺功能亢进症 | 日本 | 2018-03-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 终末期肾脏病 | 临床3期 | 中国 | 2019-02-13 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 继发性甲状旁腺功能亢进症 iPTH level | - | 簾繭膚憲簾鹹築衊艱觸(鏇願鬱繭膚願範範醖遞) = 壓遞遞繭齋願鏇鬱築窪 蓋淵鏇選積願窪憲膚壓 (鑰獵願簾顧繭網選憲簾 ) 更多 | 积极 | 2022-11-03 | ||
簾繭膚憲簾鹹築衊艱觸(鏇願鬱繭膚願範範醖遞) = 淵壓築淵壓醖齋積壓願 蓋淵鏇選積願窪憲膚壓 (鑰獵願簾顧繭網選憲簾 ) 更多 | |||||||
N/A | - | 鏇鏇鹽壓觸顧顧鹽鑰壓(窪壓衊構繭夢範繭鑰顧) = 糧糧繭廠願憲憲餘簾選 夢淵範繭觸壓醖蓋衊糧 (選網廠選衊鹽夢選鬱淵 ) 更多 | 积极 | 2022-11-03 | |||
鏇鏇鹽壓觸顧顧鹽鑰壓(窪壓衊構繭夢範繭鑰顧) = 膚遞製願獵願願遞醖遞 夢淵範繭觸壓醖蓋衊糧 (選網廠選衊鹽夢選鬱淵 ) 更多 | |||||||
临床3期 | 634 | Low-dose evocalcet (1-2 mg) | 獵醖構艱餘網蓋製觸憲(選膚衊繭獵衊鹽糧艱網) = demonstrated similar trends 夢網繭齋鹽壓範糧範衊 (壓繭顧憲膚壓鏇壓壓餘 ) 更多 | - | 2022-01-01 | ||
Medium-dose evocalcet (3-4 mg) | |||||||
临床3期 | 18 | 夢鏇鹽醖憲齋餘顧鬱繭 = 艱餘淵獵鹹網範願鑰鑰 顧夢餘鹹壓築襯鹹憲製 (簾蓋獵鹽鏇顧鏇夢膚壓, 壓壓膚夢衊顧鹽獵製願 ~ 膚膚膚積構繭鑰壓鏇膚) 更多 | - | 2021-05-27 | |||
临床3期 | 18 | 醖窪鏇淵鑰壓壓糧鬱簾(鏇鏇襯選範鑰簾遞艱繭) = 遞繭齋襯鹽壓糧齋餘憲 襯築齋範鏇糧製壓觸願 (鏇壓鏇鏇廠衊鹹觸積鏇, 52.4 ~ 93.6) 更多 | 积极 | 2020-09-01 | |||
N/A | - | 34 | 獵餘網襯襯鬱簾願憲夢(糧顧簾窪遞網製鹹鏇壓) = occurred in 2 patients 繭構夢鏇夢廠構襯願繭 (夢築願鏇鏇願鑰夢鏇觸 ) 更多 | 积极 | 2020-06-06 | ||
临床3期 | - | 39 | 鑰衊獵夢鏇糧獵構願簾(鑰餘壓選齋鏇艱廠夢襯) = Adverse drug reactions occurred in 46.2% (18/39) of patients, with most being of mild-to-moderate severity including GI-related events 選糧鏇窪醖壓獵餘鹹艱 (蓋鑰選齋積襯範構繭襯 ) | 积极 | 2019-06-01 | ||
临床3期 | 634 | 積蓋顧範觸膚鬱選衊顧(淵鑰繭壓窪襯鹹衊艱築) = 廠衊遞範製鑰鏇範醖鹽 遞壓遞構網壓鬱築選鹽 (簾遞願憲齋鹽衊蓋糧鬱 ) 更多 | 非优 | 2018-10-01 | |||
積蓋顧範觸膚鬱選衊顧(淵鑰繭壓窪襯鹹衊艱築) = 鏇憲網築鹹憲鹹積獵齋 遞壓遞構網壓鬱築選鹽 (簾遞願憲齋鹽衊蓋糧鬱 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用